The European Union is ready to discuss the proposal, now supported by the United States, to temporarily waive intellectual property rights for Covid-19 vaccines. This statement was made by Ursula von der Leyen, president of the European Commission, EUobserver reports.
"The EU is also ready to discuss any proposals that addresses the crisis in an effective and pragmatic manner. That's why we are ready to discuss how the US proposal for a waiver on intellectual property protections for Covid-19 vaccines could help achieve that objective," European Commission president Ursula von der Leyen said.
The call was first initiated by India and South Africa in the World Trade Organization (WTO) in October 2020, and since then, it has steadily gained momentum.
Now more than 100 countries have backed the waiver, together with the World Health Organization (WHO), at least 375 civil society groups, plus former heads of state, Nobel laureates, MEPs, medical experts and trade unions.
On Wednesday, the administration of US president Joe Biden announced that it would also support easing patent rules on Covid-19 vaccines, arguing that the extraordinary circumstances caused by the pandemic required extraordinary measures.
Meanwhile, Ukraine's Healthcare Minister Maksym Stepanov met with Cyrus Poonawalla, the owner of Serum Institute of India. The officials discussed the supplies of vaccines from Covid-19, namely NovaVax and AstraZeneca/CoviShield.
The sides discussed possible increase of supplies of Novavax from 10 to 15 million doses already this year, and the increase of volume of the first batch of vaccines from two to four million doses. "Already in July-August, we expect first batches of NovaVax (...) Mr. Poonawalla and I discussed the opportunity to increase the volume of supplies of NovaVax from 10 to 15 million [doses] this year," the message reads.